Fluoropyrimidines (FU) in combination with warfarin (WF) are reported to increase prothrombin time-international normalized ratio (PT-INR) and bleeding. In the present study, we investigated retrospectively the timing of expression of blood coagulation abnormality in 11 patients treated with WF and UFT or S-1 concomitantly in Okayama University Hospital and Ako City Hospital. In 11 patients, 6 were UFT in combination with WF (UFT group), 5 were S-1 in combination with WF (S-1 group). In all patients, PT-INR was significantly increased after combination with UFT or S-1. The PT-INR elevated rate of the S-1 group was 214.5% and its rate of the UFT group was 178.2%. The PT-INR elevated rate was higher in the S-1 group than in the UFT group. The PT-INR was increased 2.8 times after four months in the UFT group. These results suggest that the careful monitoring of PT-INR elevation and bleeding is necessary in patients receiving UFT in combination with WF as well as S-1 in combination with WF.
The in vitro dissolution rate of 3 commercial phenytoin (PHT) products with different particle sizes (PHT A-1, A-2 from manufacturer A, and PHT B from manufacturer B) was examined by USP rotating basket method. The difference of the dissolution rate was due to the difference in particle sizes. Particularly in the 1st fluid, 2nd fluid and borate buffer with 0.1% Polysorbate 80, the dissolution rate was significantly enhanced in the order of PHT A-l
This study investigated the influence of treatment with statins on the effect of sitagliptin in obese patients with diabetes. We studied 52 patients with type 2 obese diabetes who were started on sitagliptin from April 1, 2010 to March 31, 2012. Of these patients, 31 were taking a statin and 21 were not. HbA1c levels were measured at 0 and 3, 6, and 9 months after initiation of sitagliptin. In obese patients (BMI ≧ 25 kg/m 2), a significant improvement in HbA1c levels was observed only in those taking statins. Our findings suggest that statins may modify the glucose-lowering effect of sitagliptin in obese patients with type 2 diabetes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.